Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glimepiride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 known ✓ | Q09428 | 2/20 | 0.44 |
| ▸ | KCNJ11 known ✓ | Q14654 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.78 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.78 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.78 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.78 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glimepiride SCHEMBL16086 | 0.88 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL1331215 | 0.88 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL16084 | 0.88 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL14965363 | 0.88 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL5081711 | 0.87 | CYP2C9 (0.98) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL20877218 | 0.87 | CYP2C9 (0.98) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| SCHEMBL11189249 | 0.87 | CYP2C9 (0.86) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL28086181 | 0.87 | CYP2C9 (0.85) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL6381985 | 0.86 | CYP2C9 (0.95) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL28086735 | 0.84 | CYP2C9 (0.72) | CYP2C9ABCC3ABCC4ABCB11HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | SDG, INC. | 2012-02-09 | — | — | US | claimed |
| US-20230257653-A1 | FRACTAL FORMULATIONS | NANOGYRE Sprl (BE) | 2023-08-17 | — | — | US | disclosed |
| EP-2494075-A2 | TEMPLATED NANOCONJUGATES | Northwestern University (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2473160-A1 | DELIVERY OF THERAPEUTIC AGENTS USING OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS CARRIERS | Northwestern University (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011053940-A2 | TEMPLATED NANOCONJUGATES | NORTHWESTERN UNIVERSITY (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011028850-A1 | DELIVERY OF THERAPEUTIC AGENTS USING OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS CARRIERS | NORTHWESTERN UNIVERSITY (US) | 2011-03-10 | — | — | WO | disclosed |
| EP-2190428-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100099091-A1 | GENETIC COMPONENT OF COMPLICATIONS IN TYPE 2 DIABETES | HAMET PAVEL | 2010-04-22 | — | — | US | disclosed |
| WO-2009025784-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | IAPP, IDE, INSR | ABCC8 254/4885KCNJ11 279/4885CYP2C9 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.